Home  |  Contact

UniProtKB/Swiss-Prot P11245: Variant p.Arg268Lys

Arylamine N-acetyltransferase 2
Gene: NAT2
Variant information Variant position: help 268 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LB/B The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Arginine (R) to Lysine (K) at position 268 (R268K, p.Arg268Lys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are large size and basic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Polymorphism: help Polymorphisms in NAT2 are the cause of slow and fast acetylation phenotypes [MIM:243400] and influence drug therapy response and susceptibility to chemical toxicity or carcinogenicity. Additional information on the polymorphism described.
Variant description: help In allele NAT2*5A, allele NAT2*5D, allele NAT2*5E, allele NAT2*6A, allele NAT2*6B, allele NAT2*6D, allele NAT2*7A, allele NAT2*7B, NAT2*14A, allele NAT2*14B, allele NAT2*14D, allele NAT2*17, allele NAT2*18, allele NAT2*19. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.

Sequence information Variant position: help 268 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 290 The length of the canonical sequence.
Location on the sequence: help DNTDLVEFKTLTEEEVEEVL R NIFKISLGRNLVPKPGDGSL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.







Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
Chain 1 – 290 Arylamine N-acetyltransferase 2
Binding site 287 – 287
Helix 260 – 269

Literature citations
Nucleotide sequence of an intronless gene for a human arylamine N-acetyltransferase related to polymorphic drug acetylation.
Grant D.M.; Blum M.; Demierre A.; Meyer U.A.;
Nucleic Acids Res. 17:3978-3978(1989)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANT LYS-268; Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression.
Blum M.; Grant D.M.; McBride W.; Heim M.; Meyer U.A.;
DNA Cell Biol. 9:193-203(1990)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANT LYS-268; Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver.
Ohsako S.; Deguchi T.;
J. Biol. Chem. 265:4630-4634(1990)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; VARIANTS LYS-268 AND GLU-286; Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver.
Deguchi T.;
J. Biol. Chem. 267:18140-18147(1992)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE NAT2*6D); VARIANTS GLN-197; LYS-268 AND GLU-286; Cloning, expression, and functional characterization of two mutant (NAT2(191) and NAT2(341/803)) and wild-type human polymorphic N-acetyltransferase (NAT2) alleles.
Ferguson R.J.; Doll M.A.; Rustan T.D.; Gray K.; Hein D.W.;
Drug Metab. Dispos. 22:371-376(1994)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES NAT2*5C AND NAT2*14); VARIANTS GLN-64; THR-114 AND LYS-268; Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes.
Patin E.; Barreiro L.B.; Sabeti P.C.; Austerlitz F.; Luca F.; Sajantila A.; Behar D.M.; Semino O.; Sakuntabhai A.; Guiso N.; Gicquel B.; McElreavey K.; Harding R.M.; Heyer E.; Quintana-Murci L.;
Am. J. Hum. Genet. 78:423-436(2006)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS ILE-24; GLN-64; THR-114; MET-193; GLN-197; HIS-208; LYS-268 AND GLU-286; Submission
Leff M.A.; Doll M.A.; Feng Y.; Fretland A.J.; Hein D.W.;
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES NAT2*5D; NAT2*6D; NAT2*14G); VARIANTS GLN-64; THR-114; GLN-197 AND LYS-268; A novel linkage of two NAT2 mutations.
Banerjee M.; Anitha A.;
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS THR-114 AND LYS-268; Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201).
Ebert L.; Schick M.; Neubert P.; Schatten R.; Henze S.; Korn B.;
NIEHS SNPs program;
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS ILE-24; GLN-64; THR-114; GLN-197; LEU-228; LYS-268 AND GLU-286; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.